Miguel Tejedor-Alonso A
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Miguel Tejedor-Alonso A has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Ana González Moreno
Allergy Unit Hospital Universitario Fundación Alcorcón Madrid Spain
2 shared publications Ana Rosado Ingelmo
Hospital Universitario Fundación Alcorcón
2 shared publicationsElia Pérez-Fernández
University Hospital Fundación Alcorcón
2 shared publicationsMarianela Brandoni Petroni
Hospital Universitario Fundación Alcorcón
2 shared publications- Ana González Moreno
Departamento de Biología Molecular y Bioquímica, Instituto de Hortofruticultura Subtropical y Mediterránea “La Mayora”, Universidad de Málaga-Consejo Superior de Investigaciones Científicas, Universidad de Málaga, 29071 Málaga, Spain
1 shared publication - Ana Nieto
University of Salamanca, Spain
1 shared publication
Latest Publications
- Open Access
- 25 July 2024
- Published by Wiley
Natural history of cross intolerance to non-steroidal anti-inflammatory drugs in the paediatric population
Background : Non-steroidal anti-inflammatory drugs (NSAIDs) are one of the main causes of hypersensitivity to drugs in the paediatric population. Studies about the natural history of cross-intolerance reactions to NSAIDs are scarce. The aim of this study was to assess cross intolerance to NSAIDs over time in the paediatric population. Methods : Retrospective study in patients under 18 years old diagnosed with cross intolerance to NSAIDs by oral challenge test between 1999 and 2019. These patients were prospectively re-assessed in 2021-2022 by challenge with acetylsalicylic acid (ASA). Patient characteristics and potential factors that might have helped them develop tolerance to NSAIDs were analysed. Results : Between 1999 and 2019, 46 patients were diagnosed with cross intolerance to NSAIDs; of these, 19 were re-assessed at a second visit after a mean of 116 months from initial diagnosis. The NSAID most involved in reactions was ibuprofen. At Visit 2, it was observed that 15 (78.9%) patients tolerated ASA and other NSAIDs. Patients with atopy and who initially presented with asthma were more likely to maintain their diagnosis of cross intolerance to NSAIDs ( p =0.001 and p =0.035, respectively). On the contrary, most patients with initial angioedema developed tolerance over time ( p =0.035). Conclusion : Patients with cross intolerance to NSAIDs may develop tolerance to them over time. This tolerance might be determined both by the presence of atopy and the initial history of the patient.
- 25 July 2024
- Published by Wiley
Open AccessNatural history of cross intolerance to non-steroidal anti-inflammatory drugs in the paediatric population
Background : Non-steroidal anti-inflammatory drugs (NSAIDs) are one of the main causes of hypersensitivity to drugs in the paediatric population. Studies about the natural history of cross-intolerance reactions to NSAIDs are scarce. The aim of this study was to assess cross intolerance to NSAIDs over time in the paediatric population. Methods : Retrospective study in patients under 18 years old diagnosed with cross intolerance to NSAIDs by oral challenge test between 1999 and 2019. These patients were prospectively re-assessed in 2021-2022 by challenge with acetylsalicylic acid (ASA). Patient characteristics and potential factors that might have helped them develop tolerance to NSAIDs were analysed. Results : Between 1999 and 2019, 46 patients were diagnosed with cross intolerance to NSAIDs; of these, 19 were re-assessed at a second visit after a mean of 116 months from initial diagnosis. The NSAID most involved in reactions was ibuprofen. At Visit 2, it was observed that 15 (78.9%) patients tolerated ASA and other NSAIDs. Patients with atopy and who initially presented with asthma were more likely to maintain their diagnosis of cross intolerance to NSAIDs ( p =0.001 and p =0.035, respectively). On the contrary, most patients with initial angioedema developed tolerance over time ( p =0.035). Conclusion : Patients with cross intolerance to NSAIDs may develop tolerance to them over time. This tolerance might be determined both by the presence of atopy and the initial history of the patient.
- Open Access
- 16 July 2024
- Published by Wiley
Natural history of cross intolerance to non-steroidal anti-inflammatory drugs in the pediatric population
- 16 July 2024
- Published by Wiley
Open AccessNatural history of cross intolerance to non-steroidal anti-inflammatory drugs in the pediatric population
- 12 January 2023
- Published by S. Karger AG in International Archives of Allergy and Immunology
- Vol. 184 (4) , 353-365
Analysis of the Safety of Drug Allergy Workups in a Spanish University Hospital: Drug Characteristics, Type of Reaction, and Patients’ Age at the Initial Assessment
Introduction: The drug provocation test (DPT) is the gold standard for the drug allergy workup; however, it is not free from severe adverse reactions. Our aim was to obtain robust data that predict a reaction during or after the DPT at the first contact with the patient in the allergy outpatient clinic. Methods: The population of this cross-sectional study comprised all patients undergoing a drug allergy workup (clinical assessment, specific IgE, or skin tests, or DPT) at University Hospital Fundacion Alcorcon in 2016. DPTs were performed until therapeutic doses were reached, and late reactions were checked. The clinical disorders assessed in our study were classified mainly as absence of allergic reactions, morbilliform rash, urticaria, anaphylaxis, and other cutaneous disorders. Results: Physicians from the Allergy Unit programmed drug allergy workups in 977 patients (median age, 52 years; women, 64.54%). DPTs were not performed for 165 drugs involved in the reactions. Patients who did not undergo DPT were older than patients who did (positive or negative) (p = 0.0001). Positive DPT results were detected in 6.00% of DPTs performed, and most were for amoxicillin and metamizole (15–25% each). Multinomial logistic regression showed that positive reactions were more probable after DPT if the same clinical disorder was diagnosed at the first visit, including the episodes not considered allergic episodes (OR = 0.2, p < 0.001). Conclusion: We conclude that clinical practice in the diagnosis of drug allergy in our Allergy Department is safe, without over-diagnosis.
- 12 January 2023
- Published by S. Karger AG in International Archives of Allergy and Immunology
- Vol. 184 (4) , 353-365
Analysis of the Safety of Drug Allergy Workups in a Spanish University Hospital: Drug Characteristics, Type of Reaction, and Patients’ Age at the Initial Assessment
Introduction: The drug provocation test (DPT) is the gold standard for the drug allergy workup; however, it is not free from severe adverse reactions. Our aim was to obtain robust data that predict a reaction during or after the DPT at the first contact with the patient in the allergy outpatient clinic. Methods: The population of this cross-sectional study comprised all patients undergoing a drug allergy workup (clinical assessment, specific IgE, or skin tests, or DPT) at University Hospital Fundacion Alcorcon in 2016. DPTs were performed until therapeutic doses were reached, and late reactions were checked. The clinical disorders assessed in our study were classified mainly as absence of allergic reactions, morbilliform rash, urticaria, anaphylaxis, and other cutaneous disorders. Results: Physicians from the Allergy Unit programmed drug allergy workups in 977 patients (median age, 52 years; women, 64.54%). DPTs were not performed for 165 drugs involved in the reactions. Patients who did not undergo DPT were older than patients who did (positive or negative) (p = 0.0001). Positive DPT results were detected in 6.00% of DPTs performed, and most were for amoxicillin and metamizole (15–25% each). Multinomial logistic regression showed that positive reactions were more probable after DPT if the same clinical disorder was diagnosed at the first visit, including the episodes not considered allergic episodes (OR = 0.2, p < 0.001). Conclusion: We conclude that clinical practice in the diagnosis of drug allergy in our Allergy Department is safe, without over-diagnosis.
- Open Access
“FREQUENCY OF FATAL AND RECURRENT ANAPHYLAXIS DUE TO COW’S MILK: A SYSTEMATIC REVIEW AND META-ANALYSIS OF OBSERVATIONAL STUDIES”.
Background: Cow’s milk allergy can result in anaphylactic reactions. The estimated prevalence of cow’s milk allergy in developed countries ranges from 0.5% to 3% at age 1 year. Objective: Our objective was to perform a systematic review and, if possible, a meta-analysis to assess the frequency of fatal and recurrent anaphylaxis induced by cow’s milk. Methods: We searched PubMed/MEDLINE, EMBASE, and the Web of Science for studies that had assessed fatal and recurrent anaphylaxis induced by cow’s milk for the population of a country or at least an administrative region. Our review included cohort, cross-sectional, and registry studies that had assessed the incidence or prevalence of recurrent anaphylaxis or the incidence of fatal anaphylaxis due to cow’s milk. Results: The pooled prevalence of recurrence (PR) for at least an episode of anaphylaxis was 26.98% (3.41-155.19). Teymourpour et al (Iran) reported the highest PR (53.10%); the 2 studies with the lowest PR were from France (5.16 and 0.42 respectively) (p2 =75.91%). Levy et al and Bassagio et al reported the highest incidence rate (IR 0.15 and 0.6 deaths per million persons-year). Conclusion: The PR of anaphylaxis was approximately one quarter of patients with anaphylaxis due to cow’s milk, while deaths from anaphylaxis caused by cow’s milk were very rare, although some studies report rates as high as 15 times the lowest IR.
Open Access“FREQUENCY OF FATAL AND RECURRENT ANAPHYLAXIS DUE TO COW’S MILK: A SYSTEMATIC REVIEW AND META-ANALYSIS OF OBSERVATIONAL STUDIES”.
Background: Cow’s milk allergy can result in anaphylactic reactions. The estimated prevalence of cow’s milk allergy in developed countries ranges from 0.5% to 3% at age 1 year. Objective: Our objective was to perform a systematic review and, if possible, a meta-analysis to assess the frequency of fatal and recurrent anaphylaxis induced by cow’s milk. Methods: We searched PubMed/MEDLINE, EMBASE, and the Web of Science for studies that had assessed fatal and recurrent anaphylaxis induced by cow’s milk for the population of a country or at least an administrative region. Our review included cohort, cross-sectional, and registry studies that had assessed the incidence or prevalence of recurrent anaphylaxis or the incidence of fatal anaphylaxis due to cow’s milk. Results: The pooled prevalence of recurrence (PR) for at least an episode of anaphylaxis was 26.98% (3.41-155.19). Teymourpour et al (Iran) reported the highest PR (53.10%); the 2 studies with the lowest PR were from France (5.16 and 0.42 respectively) (p2 =75.91%). Levy et al and Bassagio et al reported the highest incidence rate (IR 0.15 and 0.6 deaths per million persons-year). Conclusion: The PR of anaphylaxis was approximately one quarter of patients with anaphylaxis due to cow’s milk, while deaths from anaphylaxis caused by cow’s milk were very rare, although some studies report rates as high as 15 times the lowest IR.
- Open Access
- 1 February 2018
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 141 (2) , AB35
Hypersensitivity Reactions To Low Molecular Weight Heparins: A Case Series
- 1 February 2018
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 141 (2) , AB35
Open AccessHypersensitivity Reactions To Low Molecular Weight Heparins: A Case Series